Comprehensive Monitoring of Men With Prostate Cancer Cared for by "Active Surveillance

Prostate Cancer Clinical Trial

Official title: Comprehensive Monitoring of Men With Prostate Cancer Cared for by "Active Surveillance

Status Recruiting

Clinical Trial Summary

Prostate cancer is the most commonly diagnosed cancer in men. However, there is a wide range in prognosis determined by a host of factors. This study will evaluate the feasibility of guiding therapeutic intervention electronically facilitated symptom and disease monitoring in patients being followed on Active Surveillance. Additionally, we will develop a tissue and data resource to support discovery and hypothesis generation to evaluate germline and/or somatic alterations in relation to cancer-specific and overall outcomes..

Clinical Trial Description

Primary objectives:

1. Monitor cancer-specific outcomes of men who meet consensus criteria for active surveillance under one of three categories: 1) low or very low-risk prostate cancer, 2) intermediate risk with patient consent, or 3) severe medical comorbidities and high-risk localized prostate cancer or patient desire, despite recommendation

Secondary objectives:

1. Screen for a relationship between cancer-specific and clinical outcomes related to selected comorbidities.

2. Determine the feasibility of electronically facilitated symptoms and disease monitoring to guide therapeutic intervention and prompt therapeutic course correction.

3. Develop a tissue and data resource to support discovery and hypothesis generation focused on germline alterations, somatic alterations, and/or the interaction between the two in determining cancer-specific and overall outcomes ;

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

• NCT number: NCT05840484
• Study type: Observational
• Source: M.D. Anderson Cancer Center
• Contact: Christopher Logothetis, MD
• Phone: 713-563-7210
• Email: clogothe@mdanderson.org
• Status: Recruiting
• Start date: March 29, 2023
• Completion date: July 30, 2029